What Oncobox does

Oncobox is a privately held precision oncology company founded in 2015 and headquartered in Walnut, California. Its core product, Oncobox Dx, is an AI-driven diagnostic platform that performs comprehensive molecular profiling of patient tumors by analyzing DNA mutations, RNA expression, and activation levels across 378 molecular pathways. The platform generates personalized drug rankings by evaluating the predicted efficacy of 170 targeted and immunotherapy drugs for each individual patient, supported by published clinical trial outcome data intended to guide oncologist treatment selection.

The underlying technology rests on a suite of proprietary algorithms—OncoFinder for intracellular signaling pathway analysis, iPANDA for in silico pathway activation network decomposition, FloWPS for SVM-based personalization, and Shambhala for platform-agnostic data harmonization. A USPTO patent granted in 2023 protects the core RNA-based analysis method, and validation has been published in peer-reviewed journals including Nature, Frontiers in Oncology, CSH Molecular Case Studies, and BMC Bioinformatics. The company built the Atlas of Normal Tissue Expression (ANTE) from healthy donor tissue to normalize tumor gene expression data, and has reported that targeted therapy effectiveness rose from 25% to 64% across a multi-regional study of 900 late-stage cancer patients. Research has been supported by grants from Amazon and Microsoft.

The business model is a professional-services diagnostic offering: oncologists at affiliated clinics order the test by submitting tumor samples to Oncobox's laboratory, which returns a ranked drug-effectiveness report used to inform treatment planning. Distribution runs through an affiliated clinic network, with awareness built via peer-reviewed publications, case studies, and conference presence (including the 2024 WIN Symposium endorsed by ASCO). Pricing is not publicly disclosed and revenue figures are not available; the company has disclosed $120,000 in seed funding from Y Combinator in 2017 and lists 11–50 employees, indicating a small-scale, science-led commercial operation rather than a scaled commercial enterprise.

Name

Oncobox

Legal name

Oncobox

Website

https://oncobox.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Oncobox is a precision oncology company whose Oncobox Dx platform performs AI-driven tumor molecular profiling (DNA, RNA, and 378 pathways) to rank 170 targeted and immunotherapy drugs for individual cancer patients, serving oncologists at affiliated clinics globally.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

Keywords

• Cancer diagnostics
• Comprehensive genomic profiling
• Precision oncology
• Molecular pathway analysis
• Tumor RNA sequencing

Headquarters

HQ city

Walnut

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: Oncobox provides comprehensive genomic profiling services through affiliated clinics. Oncologists order the test by sending tumor samples to Oncobox's laboratory. The company generates detailed reports ranking drug effectiveness for individual patients, enabling personalized treatment planning.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Oncobox provides Oncobox Dx, an AI-driven comprehensive genomic profiling service that analyzes tumor DNA and RNA to evaluate 170 targeted and immunotherapy drugs and generate personalized drug rankings for individual cancer patients. The service is delivered through affiliated clinics: oncologists order the test, tumor samples are sent to Oncobox's laboratory, and detailed reports ranking drug effectiveness with clinical trial outcomes are returned to the physician to guide treatment planning.

Product overview

Oncobox offers Oncobox Dx, a unified AI-driven diagnostic platform that performs comprehensive tumor molecular profiling. The platform analyzes changes in DNA and RNA obtained from tumor samples, evaluates the effectiveness of 170 targeted and immunotherapy drugs, and generates personalized drug rankings tailored to individual patients. The system considers all molecular nuances of a tumor and assists healthcare providers in crafting highly effective, individualized cancer treatment plans.

Differentiator

Problem solved

Functional benefit

Brands

• Oncobox Dx: AI-driven diagnostic platform analyzing tumor DNA, RNA, and molecular pathways to help oncologists select the most effective targeted therapies for individual cancer patients. Evaluates the effectiveness of 170 novel targeted and immunotherapy drugs.

Products and services

• Oncobox Dx AI-driven comprehensive genomic profiling service that analyzes DNA mutations and RNA gene expression from a tumor sample to evaluate the effectiveness of 170 targeted and immunotherapy drugs and generate a personalized drug ranking tailored to the individual patient. Reports include lists of molecular abnormalities, ranked drug recommendations, and clinical trial outcomes to guide oncologists and tumor boards in treatment planning. Delivered through affiliated clinics, with tumor samples shipped to Oncobox's laboratory for analysis.

Quantifiable outcome

• Increased targeted therapy effectiveness from 25% to 64% in multi-regional study with 900 late-stage cancer patients
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

Two partnerships are on record, tiered minor and core.

• WIN SymposiumminorStrategic or Co-development PartnerOncobox presented findings of prospective clinical trial NCT03797297 on anticancer drug prescription using RNA sequencing at WIN Symposium 2024, endorsed by ASCO, in Abu Dhabi, UAE.
• Affiliated Clinics NetworkcoreChannel Partner/ Reseller/ DistributorOncobox has established a network of affiliated clinics where patients can access Oncobox testing by consulting with oncologists. These clinical partners facilitate tumor sample collection and serve as the primary distribution channel for diagnostic services.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Foundation Medicine: Foundation Medicine (acquired by Roche) is a leading molecular profiling diagnostics company offering comprehensive genomic profiling of tumors to guide oncology treatment decisions. Directly comparable as a precision oncology diagnostic serving oncologists with comprehensive tumor profiling reports.
• Guardant Health: Guardant Health is a leading liquid biopsy and molecular diagnostics company offering comprehensive genomic profiling (e.g., Guardant360) for advanced cancer patients. Comparable as a precision oncology diagnostic provider using genomic data to guide targeted therapy selection.
• NeoGenomics: NeoGenomics operates a network of CAP/CLIA-accredited oncology-focused laboratories providing molecular profiling and other diagnostic services for cancer patients. Comparable as a clinical-grade oncology molecular diagnostics provider serving oncologists for therapy selection.
• Natera: Natera specializes in cell-free DNA and molecular diagnostics, including oncology products such as Signatera for tumor-informed MRD monitoring. Comparable precision oncology diagnostic provider using genomic analysis to inform cancer treatment decisions.
• Exact Sciences: Exact Sciences provides molecular diagnostics for cancer screening and therapy guidance (e.g., Oncotype DX, Oncodetect). Comparable broadly as a precision oncology diagnostics company with products designed to inform cancer treatment decisions based on tumor molecular data.

Direct peers

• Tempus Labs: Tempus is an AI-driven precision medicine company that analyzes clinical and molecular data (DNA/RNA sequencing) to enable personalized cancer treatment. It competes directly with Oncobox Dx by offering multi-omic tumor profiling and drug matching reports to oncologists.
• Caris Life Sciences: Caris offers MI Profile and other comprehensive molecular profiling assays analyzing DNA, RNA, and proteins to match cancer patients with targeted therapies. Directly competes with Oncobox's comprehensive tumor profiling and drug ranking approach.
• Personalis: Personalis provides whole-genome-based ImmunoID NeXT and other tumor profiling for oncology. Comparable as a precision oncology diagnostics company providing comprehensive genomic and transcriptomic analysis to inform therapy selection and clinical trial matching.
• MolecularHealth: MolecularHealth offers a precision oncology decision-support platform that analyzes tumor genomic data to rank therapies and match patients to clinical trials. Directly comparable to Oncobox Dx's approach of using molecular profiling plus curated drug/outcome data to produce ranked recommendations.

Emerging players

• Perthera: Perthera provides AI-driven precision oncology services integrating molecular testing, therapy ranking, and clinical trial matching for cancer patients. Comparable niche/emerging peer with overlapping molecular tumor profiling and personalized treatment recommendation capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncobox